Chambers Review
Provided by Chambers
Email address
[email protected]Contact number
(202) 346-4226Share profile
Band 3
Provided by Julie Tibbets
Julie Tibbets chairs Goodwin’s Life Sciences Regulatory & Compliance practice at the firm and co-chairs Goodwin’s Rare Disease Initiative. In addition, she co-chairs Goodwin’s firmwide Attorney Review Committee.
Julie focuses her practice on FDA-regulated product development, clinical research, product marketing and enforcement as well as the intersection of each of those with corporate strategy and securities disclosure obligations. Her product areas of focus include biologics, drugs, medical devices, digital therapeutics, clinical decision support tools and mobile medical apps. She also leads the regulatory due diligence reviews of FDA-regulated M&A or investment targets, potential collaborators, and licensees, and guides the regulatory disclosures of FDA-regulated entities in their initial public offerings and follow-on offerings. Julie also works closely with the Food & Healthy Living practice team at Goodwin on the intersection of food, supplement, and cosmetic regulation with FDA’s drug and device authorities.
JD, University of North Carolina, Chapel Hill 2004 (Member, Law Review); BA, Purdue University 2001 (Highest Honors, Phi Beta Kappa).
Provided by Chambers
Provided by Chambers
Julie is very skilled in FDA matters and in understanding the regulatory landscape. She is skilled at coming up with potential solutions that let businesses move forward.
Whether we're looking for a quick gut-check or thorough analysis, we can rely on Julie. Her guidance is prompt and practical and we appreciate the bench-marking she can provide.
Julie is very skilled in FDA matters and in understanding the regulatory landscape. She is skilled at coming up with potential solutions that let businesses move forward.
Whether we're looking for a quick gut-check or thorough analysis, we can rely on Julie. Her guidance is prompt and practical and we appreciate the bench-marking she can provide.